European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

Contents lists available at ScienceDirect



European Journal of Pharmaceutics and Biopharmaceutics

journal homepage: www.elsevier.com/locate/ejpb

Research Paper

Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering

Peter Charles Griffiths*, Beatrice Cattoz, Mervat Shafik Ibrahim, Josephine Chibuzor Anuonye

Department of Pharmaceutical, Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich, Medway Campus, Central Avenue, 10 Chatham Maritime, Kent ME4 4TB, UK

ARTICLE INFO

14 Article history: 15 16 Received 15 September 2014 17 Revised 27 April 2015 18 Accepted in revised form 10 May 2015 19 Available online xxxx

- 20 Keywords:
- 21 Mucin 22 Silica
- 23
- Aluminium coated silica 24
- Poly (lactic-co-glycolic acid) (PLGA) 25
- PEGylated PLGA 26 Dynamic light scattering
- 27 Rheology
- 28

ABSTRACT

Drug delivery via the eye, nose, gastrointestinal tract and lung is of great interest as they represent patient-compliant and facile methods to administer drugs. However, for a drug to reach the systemic circulation it must penetrate the "mucus barrier". An understanding of the characteristics of the mucus barrier is therefore important in the design of mucus penetrating drug delivery vehicles e.g. nanoparticles. Here, a range of nanoparticles - silica, aluminium coated silica, poly (lactic-co-glycolic acid) (PLGA) and PEGylated PLGA – each with known but different physicochemical characteristics were examined in the presence of mucin to identify those characteristics that engender nanoparticle/mucin interactions and thus, to define "design rules" for mucus penetrating (nano)particles (MPP), at least in terms of the surface characteristics of charge and hydrophilicity. Dynamic light scattering (DLS) and rheology have been used to assess the interaction between such nanoparticles and mucin. It was found that negatively charged and hydrophilic nanoparticles do not exhibit an interaction with mucin whereas positively charged and hydrophobic nanoparticles show a strong interaction. Surface grafted poly (ethylene glycol) (PEG) chains significantly reduced this interaction. This study clearly demonstrates that the established colloid science techniques of DLS and rheology are very powerful screening tools to probe nanoparticle/mucin interactions.

© 2015 Published by Elsevier B.V.

48 1. Introduction

One of the targets that has become of great interest to scientists 50 51 is drug delivery through the eye, nose, and gastrointestinal (GI) tract and lung mucosal surfaces, these being a compliant and facile 52 method to administer drugs. This delivery route does show high 53 delivery efficiencies with fewer side effects for a wide range of 54 therapeutics [1], but in order for the therapeutic agent to gain 55 56 access to the systemic circulation and be absorbed, it must traverse 57 the mucus barrier [2].

58 Mucus is a viscoelastic gel that lines the lumen of the gastroin-59 testinal, urogenital, respiratory and eye tissues [3]. The major com-60 ponent of mucus is mucin. The term "mucin" represents a family of 61 glycosylated proteins secreted by goblet cells and the seromucous glands of lamina propria at the apical epithelium [1]. The dry 62 weight of typical mucus contains mucin (5 wt%), lipids (37 wt%), 63 proteins (39 wt%), DNA (6 wt%), and other unidentified materials. 64 65 The sialic acid and sulphate content are very high in most of the moist mucosal epithelial interfaces, thereby imparting a 66

http://dx.doi.org/10.1016/j.ejpb.2015.05.004 0939-6411/© 2015 Published by Elsevier B.V. pronounced negative charge, responsible for the rigidity of the structure *via* charge repulsion [4].

Mucus has various functions, notably in the case of exposed surfaces, to act as a barrier to prevent the access of foreign bodies to tissues and blood. Nanoparticles are therefore "trapped" by mucus due to hydrophobic, electrostatic and hydrogen bonding interactions [2] or by physical entrapment of the larger nanoparticles in the mucin network [2,5]. Nanoparticles adhering to mucus are then cleared along with the mucus [6].

In the design of a putative drug delivery nanoparticle, one may expect the nanoparticles to be able to traverse the mucus barrier if its size is smaller than the mesh size of the network (10-250 nm), and should not experience strong hydrophobic, electrostatic or hydrogen bond interactions with the mucin. Further, the nanoparticles will need to penetrate the mucus faster than its characteristic clearance rate [7]. Conventional nanoparticles commonly fail in one or more of these points and thus, to overcome this problem, to achieve longer residence times for drugs at absorption sites, there is a need to design mucus penetrating (nano)particles (MPP) [1].

Here, we show how dynamic light scattering in conjunction with - both very established colloid chemistry methodologies may be used to quantify the interaction between mucin and

84

85

86

87

88

89

30

31

32

Please cite this article in press as: P.C. Griffiths et al., Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.05.004

^{*} Corresponding author. Tel.: +44 208 331 9927. E-mail address: p.griffiths@gre.ac.uk (P.C. Griffiths).

148

155

177

178

179

180

181

182

183

184

2

P.C. Griffiths et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

nanoparticles with different surface chemistries. The study will
provide a better understanding of the complex nature of mucin/ particle interactions in terms of the surface characteristics of the
nanoparticles.

A range of nanoparticles has been adopted - conventional 94 nanoparticles such as anionic and cationic silica and the synthetic 95 biodegradable polymer poly (lactic-co-glycolic acid) (PLGA) and its 96 PEGvlated derivative, (PEG-PLGA) [8-13]. PLGA is a copolymer of 97 poly (lactic acid) (PLA) and poly (glycolic acid) (PGA) [14-17]. 98 Various drugs have been loaded in PLGA nanoparticles such as 99 paclitaxel [18], curcumin [19], clarithromycin [20], praziquantel 100 [21], doxorubicin [22,23], streptomycin [24] and siRNA [25]. 101 PEG-PLGA nanoparticles have been characterised [26-28] and 102 tested for their loading capacity with various drugs as tumour 103 104 necrosis factor alpha blocking peptide [29], isoniazid [30] and rox-105 ithromvcin [31].

106 2. Materials and methods

107 2.1. Materials

Mucin type II porcine extracted from stomach, silica Ludox[®] CL, silica Ludox[®] LS, poly (lacto-co-glycolic acid) (PLGA), PEGylated PLGA (PEG 2000 and PLGA 10,000 g mol⁻¹), PEGylated PLGA (PEG 5000 and PLGA 10,000 g mol⁻¹) and PEGylated PLGA (PEG 5000 and PLGA 55,000 g mol⁻¹) were all received as supplied Sigma-Aldrich.

114 2.2. Methods

115 2.2.1. Preparation of mucin samples

116A series of mucin solutions were prepared in 0, 1, 5, 10, 25 and117100 mM NaCl. The pH of 0 mM mucin samples was also adjusted to118pH = 1, 3, 5 and 7.

119 2.2.2. Preparation of silica Ludox[®] LS samples (silica)

The stock silica dispersion was diluted to a concentration of 0.3 wt% in 0, 1, 5, 10, 25 and 100 mM NaCl. The pH of 0 mM silica sample was adjusted to pH = 1, 3 and 7. All concentrations are expressed in terms of wt% *i.e.* g/100 ml.

2.2.3. Preparation of silica Ludox[®] CL samples (aluminium coated silica)

The stock aluminium coated silica dispersion (Al silica) was diluted to a concentration of 0.15 wt% in 0, 1, 5, 10, 25 and 100 mM NaCl. The pH of 0 mM silica sample was adjusted to 1 and 3.

130 2.2.4. Preparation of PLGA samples

A total of 0.1 g PLGA of ratio 50:50 was dissolved in ethyl 131 acetate. A total of 0.2 g(s) PVA was dissolved in H₂O. Six microlitres 132 133 of this PVA solution was mixed with 0.5 ml of the PLGA solution with probe sonication for 30 min cooled by ice. The mixture was 134 135 transferred to rounded bottom flask to evaporate the ethyl acetate 136 on the rotary evaporator for 30 min. Excess PVA was removed 137 through several centrifugation (45 min) and resuspension cycles. 138 The resultant suspension was subsequently freeze dried.

139 2.2.5. Preparation of PEGylated PLGA samples

140To prepare PEG-PLGA nanoparticles, 10 mg of PEG-PLGA (Mwt141of PEG: PLGA was 2000:5000, 5000:10000 and 5000:142 $55,000 \text{ g mol}^{-1}$) was dissolved in 1 ml of acetone. Hundred micro-143litres of this PEG-PLGA acetone solution was added dropwise to a144vigorously stirred 2 ml sample of deionised water. The acetone is145then evaporated on magnetic stirrer for 10 min. The final

concentration of PEG–PLGA was 0.2 wt%, and its pH adjusted to pH values of 1, 3, 4.5 and 7. 147

2.2.6. Dynamic light scattering

An appropriate mucin stock solution was diluted with the various nanoparticle dispersions in a 50:50 ratio and examined using Malvern Zetasizer Nanoseries ZS. Measurements were carried out at temperature of 37 °C and scattering angle 173°. DLS was used to detect diffusion and size of the mucin, nanoparticles and nanoparticles/mucin mixtures.

3. Results and discussion

Dynamic light scattering is frequently used to calculate the size 156 of colloidal nanoparticles. Under limiting conditions, the Stokes-157 Einstein equation is used to derive the size (often the diameter in 158 commercial instruments) from the measured mutual diffusion 159 coefficient. To this end, an accurate measure of the nanoparticle 160 size is only obtained if the viscosity is known, and thus, experi-161 ments are usually conducted as close to infinite dilution as is pos-162 sible. Frequently, that is not always possible, as interactions 163 between nanoparticles and polymers often depend on concentra-164 tion. Here, we have explored both experimental designs, dilute sys-165 tems and those where a network of mucin will exist, as well as 166 characterised the rheology of the system for comparison. The focus 167 of this paper was the light scattering data, although representative 168 rheology data will be discussed. Further, as background screening, 169 a series of mucin solutions spanning 0 < C_{mucin} < 10 wt% were pre-170 pared to explore the effects of pH, salt and mucin concentration on 171 mucin diffusion (data not presented). In essence, the diffusion coef-172 ficient decreases with the increase in mucin concentration for 173 C_{mucin} > 0.5 wt%, the critical overlap or "gel onset" concentration, 174 but for $C_{mucin} < 0.5 \text{ wt\%}$ was unaffected. The addition of salt or 175 changes in pH had a negligible effect on the diffusion coefficient. 176

With this insight, the quantification of interaction between mucin and silica was undertaken as a function of ionic strength and pH. Initially, negatively charged and hydrophilic nanoparticulate silica of 10–15 nm size was chosen as a "negative" control. The nanoparticle size distribution (PSD) is presented in Fig. 1.

As might be expected, the silica nanoparticle component to the combined particle size distribution for the various replicate experiments/samples, shows no change *in position or intensity* upon




Fig. 1. Representative particle size distributions for negatively charged silica (Ludox[®] LS, 0.3 wt%) in the absence and presence of 0.025 wt% mucin, pH = 7 and added ionic strength = 0 mM; ____ negatively charged silica alone; ___ negatively charged silica mucin mixture; _._ mucin alone.

Please cite this article in press as: P.C. Griffiths et al., Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.05.004

Download English Version:

https://daneshyari.com/en/article/8412987

Download Persian Version:

https://daneshyari.com/article/8412987

Daneshyari.com